Cisplatin 100mg
| Product Overview | |
| Generic Name | Cisplatin 100mg |
| Brand Name(s) | Platinol-AQ |
| Form | Intravenous solution, vial (for infusion) |
| Strength | 100 mg/100 mL |
| Therapeutic Class | Platinum-based alkylating antineoplastic agent |
| ATC Code | L01XA01 |
| Manufacturing & Regulatory | |
| Manufacturer | Bristol-Myers Squibb |
| Country | Canada, USA, India |
| GMP Compliance | WHO-GMP |
| DMF/CEP | #75-036 |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 100 units |
| Shelf Life | 24 months |
| Storage | 2–8 °C |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes—lot-specific Certificate of Analysis |
| SDS | Yes—for API and finished product |
| CTD Summary | CTD from originator; generic use abbreviated formats |
Description
Cisplatin is an injectable platinum-based chemotherapy medicine for treatment of solid tumors, including testicular, ovarian, bladder, lung, cervical, and head-and-neck cancers. Administered by intravenous infusion; requires monitoring due to potential kidney toxicity, bone marrow suppression, hearing toxicity, nausea/vomiting and electrolyte abnormalities.
